Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

BACKGROUND: anti-Programmed Death-1 (anti-PD-1) immunotherapy has shown promising manifestation in improving the survival rate of patients with advanced melanoma, with its efficacy closely linked to Programmed cell death-Ligand 1 (PD-L1) expression. However, low clinical efficacy and drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Nian, Yan, Mingjie, Tao, Qian, Wu, Jie, Chen, Jing, Chen, Xiang, Peng, Cong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496672/
https://www.ncbi.nlm.nih.gov/pubmed/37678921
http://dx.doi.org/10.1136/jitc-2023-007146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496672/
https://www.ncbi.nlm.nih.gov/pubmed/37678921
http://dx.doi.org/10.1136/jitc-2023-007146

Ejemplares similares